RESUMO
BACKGROUND: Therapeutic drug monitoring (TDM) and dose adjustment of lenvatinib may be beneficial in the treatment of radioiodine-refractory thyroid cancer, by maximizing antitumor effects and minimizing adverse drug reactions. The aim of this study was, therefore, to develop and validate a high-performance liquid chromatography method using an ultraviolet detection system for routine serum lenvatinib detection in patients with thyroid cancer. METHODS: Serum specimens, spiked with an internal standard, were treated by a solid-phase extraction through an octadecylsilyl silica cartridge. Lenvatinib and internal standard were concomitantly separated from serum using a conventional octadecylsilyl silica column through isocratic elution, using a mobile phase consisting of 0.02 mol/L sodium phosphate (pH 6.7) and acetonitrile (50/50, vol/vol) at a flow rate of 1.0 mL/min. The detection wavelength was set at 244 nm. Serum samples from 5 patients were used for clinical validation of the method. RESULTS: The calibration curve for lenvatinib was linear (Pearson correlation coefficient, r = 0.9998) over the concentration range of 6.25-400 ng/mL, with a lower limit of quantification of 6.25 ng/mL. Extraction recoveries for lenvatinib were 97% or more, with coefficients of variation less than 2.2%. The coefficients of variation for intraday and interday assays were less than 4.7% and 6.0%, respectively. CONCLUSIONS: This sensitive high-performance liquid chromatography method can be used for lenvatinib therapeutic drug monitoring when liquid chromatography-tandem mass spectrometry facilities are unavailable.
Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Monitoramento de Medicamentos/métodos , Compostos de Fenilureia/sangue , Quinolinas/sangue , Acetonitrilas/sangue , Idoso , Calibragem , Feminino , Humanos , Radioisótopos do Iodo/sangue , Limite de Detecção , Masculino , Pessoa de Meia-Idade , Reprodutibilidade dos Testes , Extração em Fase Sólida/métodosRESUMO
OBJECTIVES: In vivo evaluations of a gonadotropin releasing hormone-receptor single photon emission computed tomography radiotracer for non-invasive detection of gonadotropin releasing homone-receptors in brain. RESULTS: We have used a simple, robust and high-yielding procedure to radiolabel an alpha-halogenated bioactive compound with high radiochemical yield. Literature findings showed similar alpha-halogenated compounds suitable for in vivo evaluations. The compound was found to possess nano molar affinity for the gonadotropin releasing hormone-receptor in a competition dependent inhibition study. Furthermore, liquid chromatography-mass spectrometry analysis in saline, human and rat serum resulted in 46%, 52% and 44% stability after incubation for 1 h respectively. In addition, rat brain single photon emission computed tomography and biodistribution studies gave further insight into the nature of the compound as a radiotracer.
Assuntos
Encéfalo/diagnóstico por imagem , Encéfalo/metabolismo , Receptores LHRH/metabolismo , Tomografia Computadorizada de Emissão de Fóton Único/métodos , Animais , Humanos , Hidrocarbonetos Halogenados/sangue , Hidrocarbonetos Halogenados/química , Hidrocarbonetos Halogenados/farmacocinética , Radioisótopos do Iodo/sangue , Radioisótopos do Iodo/química , Radioisótopos do Iodo/farmacocinética , Cinética , Estrutura Molecular , Ratos , Receptores LHRH/química , Distribuição TecidualRESUMO
PURPOSE: To propose a new and effective dose regimen for stable potassium iodide (KI) repeated prophylaxis in case of prolonged exposure to radioactive iodine. METHODS: The pharmacokinetics of iodine was determined in rats by compartmental analyses after intravenous and oral administrations of the optimal dose of 1 mg/kg KI, which was previously selected in a dose-effect study. The thyroid protection against iodine-125 incorporation was followed during 24 h after a single oral dosing of KI. A repeated KI prophylaxis was modeled using initial estimates of iodine pharmacokinetic parameters. RESULTS: A dose regimen consisting in administrations of 1 mg/kg daily for 8 days was selected and studied. Plasma iodine concentrations predicted by simulation were verified by experimental data and varied after the third dose of KI between 174 and 1190 µg/l. The inhibition study of iodine-125 binding in the thyroid as a function of the time showed that the protection effect of KI could be correlated to stable iodine plasma concentrations. Hence, a theoretical decrease in iodine-125 thyroid uptake from 63 to 88% could be achieved in a 24 h-interval between two KI doses. CONCLUSION: Given the satisfactory levels of thyroid protection, this dose regimen could be envisaged in order to extent KI indications for repeated prophylaxis.
Assuntos
Radioisótopos do Iodo/efeitos adversos , Radioisótopos do Iodo/farmacocinética , Iodeto de Potássio/uso terapêutico , Substâncias Protetoras/uso terapêutico , Glândula Tireoide/efeitos dos fármacos , Glândula Tireoide/metabolismo , Administração Oral , Animais , Radioisótopos do Iodo/sangue , Masculino , Modelos Biológicos , Permeabilidade/efeitos dos fármacos , Iodeto de Potássio/administração & dosagem , Profilaxia Pré-Exposição , Substâncias Protetoras/administração & dosagem , Ratos , Ratos WistarRESUMO
Challenges facing cardiovascular imaging necessitate innovation of better radiopharmaceuticals to augment or replace the existing ones. This research assesses the ability and competency of radioiodinated esmolol as a potential cardio selective imaging agent. Radioiodinated esmolol was synthesized with 97.3⯱â¯0.3% radiochemical yield and with high stability up to 48â¯h at room temperature as well as in rat serum. Molecular modeling study was performed to confirm the binding of iodinated esmolol to ß1-adrenergic receptor. Its biodistribution studies in normal Swiss albino mice showed high heart uptake (38.5⯱â¯0.11%ID/g at 5â¯min p.i.), heart/liver ratio nearly 3.85:1 and heart/lungs ratio was about 7:1 at 5â¯min p.i. The evidenced selectivity of the radioiodinated esmolol to ß1-adrenoceptor was confirmed by prior injection of cold esmolol. Gamma camera biodistribution pattern showed that radioiodinated esmolol accumulated selectively in heart.
Assuntos
Radioisótopos do Iodo , Imagem de Perfusão do Miocárdio/métodos , Propanolaminas , Compostos Radiofarmacêuticos , Animais , Simulação por Computador , Estabilidade de Medicamentos , Coração/diagnóstico por imagem , Técnicas In Vitro , Radioisótopos do Iodo/sangue , Masculino , Camundongos , Modelos Moleculares , Imagem de Perfusão do Miocárdio/estatística & dados numéricos , Miocárdio/metabolismo , Propanolaminas/sangue , Propanolaminas/síntese química , Propanolaminas/química , Compostos Radiofarmacêuticos/sangue , Compostos Radiofarmacêuticos/síntese química , Compostos Radiofarmacêuticos/química , Ratos , Receptores Adrenérgicos beta 1/metabolismo , Distribuição TecidualRESUMO
AIM: The aim of this study was to assess the agreement between predicted blood uptake values using I and actually measured I blood uptake values (reference) in patients with differentiated thyroid carcinoma receiving largely high therapeutic activities. PATIENTS AND METHODS: Fourteen patients were analyzed retrospectively, who underwent a series of both pretherapeutic and intratherapeutic blood sampling using median I activities of 23 MBq and median therapy I activities of 10 GBq. Data of five blood samples from each patient were analyzed. Lin's concordance correlation coefficient analysis was carried out to assess the kinetic agreement. The time-integrated I activity coefficient (TIAC) for the blood compartment and the effective I clearance time (ECT), expressed as effective I half-life on the basis of a monoexponential model, were ascertained. For each patient, the (intrapatient) percentage differences between pretherapeutic and intratherapeutic TIACs and ECTs were calculated. The (interpatient) difference in TIACs and ECTs between pretherapy and intratherapy groups was evaluated using the Mann-Whitney U-test. RESULTS: Lin's concordance correlation coefficient was at least 0.97, indicating substantial kinetic agreement between pretherapeutic and intratherapeutic radioiodine kinetics. The mean (median)±SD (range) of the absolute percentage difference was 9% (11%)±7% (0.33-20%) for the TIAC and 11% (10%)±10% (0-23%) for the ECT. A slightly higher median TIAC was observed in intratherapy (2.8 vs. 3.3 h), but this was not statistically significant (P=0.15), whereas no remarkable ECT difference (P=0.62) was found. CONCLUSION: The pretherapeutic blood kinetics derived from diagnostic I activities provides a reliable estimation of the intratherapeutic I blood kinetics in patients receiving largely high therapy activities, showing its potential for radioiodine treatment planning.
Assuntos
Radioisótopos do Iodo/sangue , Radioisótopos do Iodo/uso terapêutico , Neoplasias da Glândula Tireoide/sangue , Neoplasias da Glândula Tireoide/radioterapia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Cinética , Masculino , Pessoa de Meia-Idade , Radiometria , Dosagem Radioterapêutica , Estudos Retrospectivos , Adulto JovemRESUMO
Biodistribution of [125I]Aimpila (20 mg/kg) in the tumor and normal tissues, including the mammary gland tissue, after single oral dose was studied in BALB/c nude mice with T47D/ReCAF+++ human breast tumor sensitive to this drug and in closely related BALB/c nude+mice without tumors. The maximum concentration of [125I]Aimpila was in fact the same in the tumor and in the mammary gland, while the time course of its accumulation/elimination differed. The time of the maximum accumulation of the drug in the tumor was shorter and its persistence longer than in normal tissue. After 24 h, label concentration in the tumor was 4.5 times higher (p=0.002). Differences in the time course of label accumulation in the tumor were detected. The maximum ratio of tumor/blood concentrations of the preparation was recorded in 1 h after administration. [125I]Aimpila and [125I]alpha-fetoprotein accumulated in the tumor in comparable concentrations and were eliminated simultaneously at the same rate. The results of comparative analysis of accumulation of the labeled compounds in Aimpila-sensitive T47D/RECAF+++ tumor from 0.5 to 9.0 h after drug administration could be interpreted as a result of possible receptor-mediated binding of the complex with the tumor at the expense of the alpha-fetoprotein transporting part. Differences in the parameters of [125I]Aimpila biodistribution in the tumor and normal mammary tissue indirectly attested to selective antiproliferative activity of the complex.
Assuntos
Antineoplásicos/farmacocinética , Atractilosídeo/farmacocinética , Neoplasias da Mama/tratamento farmacológico , Radioisótopos do Iodo/farmacocinética , Compostos Radiofarmacêuticos/farmacocinética , alfa-Fetoproteínas/farmacocinética , Animais , Antineoplásicos/sangue , Atractilosídeo/sangue , Disponibilidade Biológica , Neoplasias da Mama/metabolismo , Neoplasias da Mama/patologia , Feminino , Mucosa Gástrica/metabolismo , Humanos , Radioisótopos do Iodo/sangue , Jejuno/metabolismo , Fígado/metabolismo , Glândulas Mamárias Animais/metabolismo , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Compostos Radiofarmacêuticos/sangue , Suínos , Distribuição Tecidual , Ensaios Antitumorais Modelo de Xenoenxerto , alfa-Fetoproteínas/metabolismoRESUMO
Clinical trials showed renal protective effects of bovine intestinal alkaline phosphatase (AP) in patients with sepsis-associated acute kidney injury (AKI). Subsequently, a human recombinant chimeric AP (recAP) was developed as a pharmaceutically acceptable alternative. Here, we investigated the biodistribution and pharmacokinetics (PK) of recAP and developed a translational population PK model. Biodistribution was studied during LPS-induced AKI in rats. Iodine-125-labeled recAP was primarily taken up by liver, spleen, adrenals, heart, lungs and kidneys followed by the gastro-intestinal tract and thyroid. Tissue distribution was not critically affected by endotoxemia. PK parameters were determined in rats and minipigs during IV bolus injections of recAP, administered once, or once daily during seven consecutive days. Plasma concentrations of recAP increased with increasing dose and disappeared in a biphasic manner. Exposure to recAP, estimated by AUC and Cmax, was similar on days 1 and 7. Subsequently, population approach nonlinear mixed effects modeling was performed with recAP rat and minipig and biAP phase I PK data. Concentration versus time data was accurately described in all species by a two-compartmental model with allometric scaling based on body weight. This model provides a solid foundation for determining the optimal dose and duration of first-in-man recAP studies.
Assuntos
Fosfatase Alcalina/farmacocinética , Modelos Biológicos , Proteínas Recombinantes/farmacocinética , Injúria Renal Aguda/induzido quimicamente , Injúria Renal Aguda/diagnóstico por imagem , Fosfatase Alcalina/sangue , Animais , Relação Dose-Resposta a Droga , Humanos , Radioisótopos do Iodo/sangue , Radioisótopos do Iodo/farmacocinética , Lipopolissacarídeos , Cintilografia , Ratos , Proteínas Recombinantes/sangue , Suínos , Porco Miniatura , Distribuição TecidualRESUMO
The amount of 131I necessary for successful ablation in patients with differentiated thyroid cancer (DTC) is still subject to debate. This study investigates the relationship of the absorbed dose of radiation to the blood while administering 131I activity with several other parameters in DTC patients. This prospective study included 90 DTC patients who were classified into three groups according to their level of dosage: 3.7 GBq (38.9%), 5.55 GBq (55.6%), and 7.4 GBq (5.5%). Blood dosimetry of treated patients was performed using external whole-body counting with a Geiger Muller dosimeter located 2 m away from the patients. Dose rate was measured at 2, 4, 5, 24, and 48 h after the administration of radioiodine. Based on the results of whole-body dose rate measurements, 48 h after administration of 3.7, 5.55, and 7.4 GBq of radioiodine, absorbed doses to patients' blood were estimated at 0.49 ± 0.12, 0.71 ± 0.21, and 0.76 ± 0.11 Gy, respectively. Increasing radioiodine dosage from 3.7 GBq to 5.55 GBq significantly increased blood dose, while there was no significant difference in blood dose between radioiodine dosages of 5.55 GBq and 7.4 GBq. The absorbed dose to the blood was significantly correlated to the patients' gender and the presence of lymph node metastases, but it was not significantly correlated to the type of pathology and regional or distant metastases. Ablation activities exceeding 5.55 GBq produce no further increase in the accumulated activity per volume of blood. The literature regarding this issue is scarce, and further studies are required to verify these preliminary results.
Assuntos
Radioisótopos do Iodo/uso terapêutico , Neoplasias da Glândula Tireoide/radioterapia , Adenocarcinoma Folicular/sangue , Adenocarcinoma Folicular/radioterapia , Adenocarcinoma Folicular/secundário , Adulto , Carcinoma Papilar/sangue , Carcinoma Papilar/radioterapia , Carcinoma Papilar/secundário , Feminino , Humanos , Radioisótopos do Iodo/administração & dosagem , Radioisótopos do Iodo/sangue , Metástase Linfática/radioterapia , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Dosagem Radioterapêutica , Neoplasias da Glândula Tireoide/sangue , Contagem Corporal Total/métodosRESUMO
Excess body fat or obesity is known to increase risk of poor vitamin D status in nonathletes but it is not known if this is the case in athletes. Furthermore, the reason for this association is not understood, but is thought to be due to either sequestration of the fat-soluble vitamin within adipose tissue or the effect of volume dilution related to obese individuals' larger body size. Forty two US college athletes (24 men 18 women, 20.7 ± 1.6 years, 85.0 ± 28.7 kg, BMI = 25.7 ± 6.1 kg/m2) provided blood samples during the fall and underwent measurement of body composition via dual energy X-ray absorptiometry. Serum samples were evaluated for 25-hydroxyvitamin D (25(OH)D) concentration to assess vitamin D status using Diasorin 25(OH)D radioiodine assay. Serum 25(OH)D concentration was negatively associated with height (r = -0.45), total body mass (r = -0.57), BMI (r = -0.57), body fat percentage (r = -0.45), fat mass (r = -0.60) and fat-free mass (r = -0.51) (p < .05). These associations did not change after controlling for sex. In a linear regression mixed model, fat mass (coefficient -0.47, p = .01), but not fat-free mass (coefficient -0.18, p = .32) significantly predicted vitamin D status and explained approximately 36% of the variation in serum 25(OH)D concentration. These results suggest that athletes with a large body size and/or excess adiposity may be at higher risk for vitamin D insufficiency and deficiency. In addition, the significant association between serum 25(OH)D concentration and fat mass in the mixed model, which remained after controlling for sex, is in support of vitamin D sequestration rather than volume dilution as an explanation for such association.
Assuntos
Tecido Adiposo/metabolismo , Composição Corporal , Índice de Massa Corporal , Obesidade/complicações , Esportes/fisiologia , Deficiência de Vitamina D/etiologia , Vitamina D/análogos & derivados , Absorciometria de Fóton , Adiposidade , Adulto , Atletas , Compartimentos de Líquidos Corporais/metabolismo , Tamanho Corporal , Feminino , Humanos , Radioisótopos do Iodo/sangue , Masculino , Obesidade/sangue , Vitamina D/sangue , Deficiência de Vitamina D/sangue , Vitaminas/sangue , Adulto JovemRESUMO
In this study, the regional rat brain distribution of radioiodinated o-iodo-trans-decalinvesamicol ([(125) I]OIDV) was determined in vivo to evaluate its potential as a single-photon emission computed tomography (SPECT) imaging probe for vesicular acetylcholine transporter (VAChT). Following intravenous injection, [(125) I]OIDV passed freely across the blood-brain barrier and accumulated in rat brain. The accumulation of [(125) I]OIDV in rat brain was significantly reduced by coadministration of (+/-)-vesamicol (0.125 µmol). In contrast, the coadministration of σ-receptor ligands, such as (+)-pentazocine (0.125 µmol) as a σ-1 receptor ligand and (+)-3-(3-hydroxyphenyl)-N-propylpiperidine (0.125 µmol) as a σ-1 and σ-2 receptor ligands, barely affected the accumulation of [(125) I]OIDV in rat brain. These findings in vivo were corroborated by autoradiographic analysis ex vivo. The authors found that the tracer binds with pharmacological selectivity to VAChT in rat brain and predicted that it may likewise serve in translational SPECT imaging studies of this marker in the integrity of cholinergic innervations.
Assuntos
Encéfalo/diagnóstico por imagem , Encéfalo/metabolismo , Piperidinas , Proteínas Vesiculares de Transporte de Acetilcolina/metabolismo , Animais , Autorradiografia , Barreira Hematoencefálica/metabolismo , Radioisótopos do Iodo/sangue , Radioisótopos do Iodo/farmacocinética , Ligantes , Masculino , Antagonistas de Entorpecentes/farmacologia , Pentazocina/farmacologia , Piperidinas/sangue , Piperidinas/farmacocinética , Piperidinas/farmacologia , Ratos , Ratos Sprague-Dawley , Receptores sigma/antagonistas & inibidores , Receptores sigma/metabolismo , Tomografia Computadorizada de Emissão de Fóton Único , Receptor Sigma-1RESUMO
Based on animal model studies, [131I]IAZA may be useful as an adjunct radiotherapeutic (MRT) drug for the treatment of tumor hypoxia. However, radioactivity in the blood of patients and healthy volunteers dosed with [123I]IAZA has a protracted terminal elimination phase in which clearance is influenced by free [123I]IAZA and possibly by unidentified metabolites. The current work reports that about 40% of the radioactivity in human serum is associated with the serum protein fraction, and that the free:bound ratio is constant at about 60:40 for at least the first 135 min after injection, as determined by radio-HPLC analyses. In order to modulate the clearance of bound and free radioactive IAZA, nonradioactive (cold) IAZA was administered i.v. 1 h following injection of high specific activity [125I][IAZA in the Balb/C EMT-6 murine tumor model. This 'wash out' procedure reduced the concentrations of radioactivity by at least 40% in all tissues, with greatest effect in kidney and liver, and least in tumor. As a result, the tumor:blood ratio increased from 5.8 to 8.5 at 4 h post-injection. This effect would be advantageous for the use of [131I]IAZA as an MRT drug. Optimization of intervals between radioactive and wash out dose, and confirmation of the self-irradiation dose to all tissues, remain to be undertaken before [131I]IAZA can be tested as a low-dose-rate MRT supplement to external beam x-ray radiotherapy.
Assuntos
Neoplasias Experimentais/tratamento farmacológico , Nitroimidazóis/farmacocinética , Compostos Radiofarmacêuticos/farmacocinética , Animais , Temperatura Baixa , Voluntários Saudáveis , Humanos , Radioisótopos do Iodo/sangue , Radioisótopos do Iodo/farmacocinética , Camundongos , Camundongos Endogâmicos BALB C , Neoplasias Experimentais/sangue , Nitroimidazóis/sangue , Compostos Radiofarmacêuticos/sangue , Distribuição TecidualRESUMO
Radioactive iodide ((131)I-) protection studies have focused primarily on the thyroid gland and disturbances in the hypothalamic-pituitary-thyroid axis. The objective of the current study was to establish (131)I- urinary excretion profiles for saline, and the thyroid protectants, potassium iodide (KI) and ammonium perchlorate over a 75 hour time-course. Rats were administered (131)I- and 3 hours later dosed with either saline, 30 mg/kg of NH(4)ClO(4) or 30 mg/kg of KI. Urinalysis of the first 36 hours of the time-course revealed that NH(4)ClO(4) treated animals excreted significantly more (131)I- compared with KI and saline treatments. A second study followed the same protocol, but thyroxine (T(4)) was administered daily over a 3 day period. During the first 6-12 hour after (131)I- dosing, rats administered NH(4)ClO(4) excreted significantly more (131)I- than the other treatment groups. T(4) treatment resulted in increased retention of radioiodide in the thyroid gland 75 hour after (131)I- administration. We speculate that the T(4) treatment related reduction in serum TSH caused a decrease synthesis and secretion of thyroid hormones resulting in greater residual radioiodide in the thyroid gland. Our findings suggest that ammonium perchlorate treatment accelerates the elimination rate of radioiodide within the first 24 to 36 hours and thus may be more effective at reducing harmful exposure to (131)I- compared to KI treatment for repeated dosing situations. Repeated dosing studies are needed to compare the effectiveness of these treatments to reduce the radioactive iodide burden of the thyroid gland.
Assuntos
Iodo/urina , Percloratos/uso terapêutico , Iodeto de Potássio/uso terapêutico , Compostos de Amônio Quaternário/uso terapêutico , Lesões por Radiação/prevenção & controle , Doenças da Glândula Tireoide/prevenção & controle , Animais , Iodo/sangue , Iodo/farmacocinética , Radioisótopos do Iodo/sangue , Radioisótopos do Iodo/farmacocinética , Radioisótopos do Iodo/urina , Masculino , Percloratos/sangue , Percloratos/urina , Ratos , Ratos Sprague-Dawley , Glândula Tireoide/metabolismo , Tireotropina/sangueRESUMO
Several dosimetric methods have been proposed for estimating red marrow absorbed dose (RMAD) when radionuclide therapy is planned for differentiated thyroid cancer, although to date, there is no consensus as to whether dose calculation should be based on blood-activity concentration or not. Our purpose was to compare RMADs derived from methods that require collecting patients' blood samples versus those involving OLINDA/EXM software, thereby precluding this invasive procedure. This is a retrospective study that included 34 patients under treatment for metastatic thyroid disease. A deviation of <10 % between RMADs was found, when comparing the doses from the most usual invasive dosimetric methods and those from OLINDA/EXM. No statistical difference between the methods was discovered, whereby the need for invasive procedures when calculating the dose is questioned. The use of OLINDA/EXM in clinical routine could possibly diminish data collection, thus giving rise to a simultaneous reduction in time and clinical costs, besides avoiding any kind of discomfort on the part of the patients involved.
Assuntos
Medula Óssea/metabolismo , Radioisótopos do Iodo/farmacocinética , Dosagem Radioterapêutica , Software , Neoplasias da Glândula Tireoide/radioterapia , Absorção , Adulto , Idoso , Medula Óssea/efeitos da radiação , Feminino , Humanos , Radioisótopos do Iodo/sangue , Radioisótopos do Iodo/uso terapêutico , Masculino , Pessoa de Meia-Idade , Compostos Radiofarmacêuticos/sangue , Compostos Radiofarmacêuticos/farmacocinética , Compostos Radiofarmacêuticos/uso terapêutico , Estudos Retrospectivos , Neoplasias da Glândula Tireoide/secundárioRESUMO
The objective of this study was to explore the inter-relationship of three platelet measures of serotonergic function (5-HT): 5-HT Transporter Binding, 5-HT-2 Receptor Binding and 5-HT Content and to explore their inter-relationship with measures of aggression and impulsivity. 58 male subjects with personality disorder were studied. Numbers of platelet 5-HT Transporter and 5-HT-2 Receptor sites were assessed by examining the Bmax of ³H-Paroxetine Binding and the Bmax of ¹²5I-LSD Binding to the blood platelet; 5-HT Content was assessed by measuring the amount of 5-HT in the platelet material. Life history of aggression was assessed by Life History of Aggression. Impulsivity was assessed by the Impulsivity Scale of the Eysenck Personality Questionnaire-II. Platelet 5-HT Transporter Binding correlated with both 5-HT-2 Receptor Binding and 5-HT Content; the latter two variables did not correlate with each other. Only Platelet 5-HT Transporter binding correlated significantly with LHA Aggression. These data suggest that while Platelet 5-HT Transporter binding correlates with both 5-HT-2 Receptor Binding and with 5-HT Content, that only 5-HT Transporter Binding represents a correlate of aggression in male personality disordered subjects.
Assuntos
Agressão/fisiologia , Plaquetas/metabolismo , Comportamento Impulsivo/metabolismo , Transtornos da Personalidade/metabolismo , Ensaio Radioligante/psicologia , Receptores 5-HT2 de Serotonina/análise , Proteínas da Membrana Plasmática de Transporte de Serotonina/análise , Serotonina/análise , Adulto , Plaquetas/diagnóstico por imagem , Humanos , Comportamento Impulsivo/complicações , Comportamento Impulsivo/psicologia , Radioisótopos do Iodo/sangue , Dietilamida do Ácido Lisérgico , Masculino , Paroxetina , Transtornos da Personalidade/complicações , Transtornos da Personalidade/psicologia , Escalas de Graduação Psiquiátrica/estatística & dados numéricos , Ensaio Radioligante/métodos , Cintilografia , Trítio/sangueRESUMO
BACKGROUND: A new promising approach to improve the outcome of head and neck squamous cell carcinoma (HNSCC) is the application of radio-labeled antibodies directed against tumor-associated antigens. Cytokeratin 8 (CK8), an intermediate filament forming protein, is shown to be de novo expressed in dysplastic lesions as well as in HNSCC. Therefore like the epithelial cell adhesion molecule CK8 seems to be a suitable anchor molecule for targeted radioimmunotherapy (RIT). The aim of this study was to investigate the biodistribution of a radio-labeled Cytokeratin 8-specific monoclonal antibody (mAb) in a SCID (severe combined immunodeficiency disease) mouse model. MATERIALS AND METHODS: The mAb against CK8 was labeled with (131)I and biodistribution was tested in established HNSCC xenografts in SCID mice. The biodistribution of the mAb in the tumor and different organs was determined with a gamma counter and was calculated as % injected dose/gram tissue. RESULTS: Initially, after systemic administration of (131)I-anti CK8 monoclonal antibody high activity was seen in all the organs. Over time the general activity decreased, whereas activity accumulated in the tumor. This activity decayed compared to the other tissues with a two- to threefold prolonged radioactive half-life. CONCLUSION: Specific antibody-antigen-binding is probably responsible for the prolonged radioactive half-life in the tumor and the resulting cumulative activity due to enrichment of the (131)I-anti CK8 mAb, so that Cytokeratin 8 seems to be a suitable anchor molecule for radioimmunotherapy in HNSCC.
Assuntos
Anticorpos Monoclonais/farmacocinética , Carcinoma de Células Escamosas/metabolismo , Neoplasias de Cabeça e Pescoço/metabolismo , Marcação por Isótopo , Queratina-8/imunologia , Transplante Heterólogo , Ensaios Antitumorais Modelo de Xenoenxerto , Animais , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais/sangue , Antígenos de Neoplasias/imunologia , Carcinoma de Células Escamosas/sangue , Carcinoma de Células Escamosas/imunologia , Neoplasias de Cabeça e Pescoço/sangue , Neoplasias de Cabeça e Pescoço/imunologia , Humanos , Imuno-Histoquímica , Injeções Intravenosas , Radioisótopos do Iodo/administração & dosagem , Radioisótopos do Iodo/sangue , Radioisótopos do Iodo/farmacocinética , Dose Máxima Tolerável , Camundongos , Camundongos SCID , Especificidade de Órgãos , Carcinoma de Células Escamosas de Cabeça e Pescoço , Distribuição TecidualRESUMO
BACKGROUND: Occasionally, blood samples may be required from thyroid cancer patients after they have been given the therapy dose of (131)I, as part of necessary medical management of comorbidities. Thus, in the days after (131)I administration, medical health professionals may be involved in the withdrawal, handling, and manipulation of radioactive blood samples. The purpose of this study was to quantify the amount of radioactivity in blood samples taken from thyroidectomized thyroid carcinoma patients after the administration of therapeutic activities of (131)I. METHODS: For dosimetry purposes, serial blood sampling is performed on thyroidectomized thyroid carcinoma patients prior to therapy with (131)I. The quantities of radioactive material present in these blood samples were expressed as a percentage of the administered activity and then extrapolated to the high levels of (131)I used in therapy for 377 patients in this study. The corresponding radiation exposure rate from the blood samples was then calculated to determine what radiation protection methods were required for staff handling these samples. RESULTS: The average amount of radioactivity in a 1 mL blood sample at 1 hour postadministration of 5.5 GBq (150 mCi) of (131)I was 0.2 ± 0.15 MBq (5.4 ± 4.0 µCi). This corresponds to an exposure rate of 1.23 µSv/h (0.123 mrem/h) at 10 cm from the sample. For samples obtained beyond 24 hours after a therapeutic administration of 5.55 GBq (150 mCi), the exposure levels are approximately equal to background radiation. CONCLUSION: The data in this study indicate that the radiation exposure from blood samples withdrawn from thyroidectomized thyroid cancer patients is low. However, to ensure that staff members are exposed to minimal levels of radiation, it is imperative that staff members who are involved in withdrawing, handling, or manipulating radioactive blood samples adhere to the recommended radiation safety practices.
Assuntos
Carcinoma , Radioisótopos do Iodo/sangue , Radioisótopos do Iodo/uso terapêutico , Exposição Ocupacional , Lesões por Radiação/prevenção & controle , Manejo de Espécimes , Neoplasias da Glândula Tireoide , Tireoidectomia , Carcinoma/sangue , Carcinoma/radioterapia , Carcinoma/cirurgia , Humanos , Radioisótopos do Iodo/efeitos adversos , Radioisótopos do Iodo/farmacocinética , Cidade de Nova Iorque , Lesões por Radiação/etiologia , Proteção Radiológica , Radiometria , Dosagem Radioterapêutica , Radioterapia Adjuvante , Neoplasias da Glândula Tireoide/sangue , Neoplasias da Glândula Tireoide/radioterapia , Neoplasias da Glândula Tireoide/cirurgiaRESUMO
We present data on repeated iodine-131 whole body scans ((131)I-WBS) in differentiated thyroid cancer patients (DTC) after surgery and (131)I remnant ablation and on increased thyroglobulin (Tg) with negative (131)I-WBS, in a retrospective study at our hospital. A total of 106 patients (91 female and 15 male) treated with (131)I for DTC met the inclusion criteria. The mean age of the patients was 45 years, age range 16-81 years. A total of 101 patients had complete 24 months follow-up following (131)I remnant ablation treatment. The mean (131)I dose administered after the first 6 months of follow- up was 3GBq while mean total dose was 4.9GBq, range 1.1-7.4GBq. Our results showed that at the end of the first 6 months post treatment, 58/101 patients had a negative (131)I-WBS. By the end of the 4th (131)I treatment at 24th months, the remaining 43 patients became negative for (131)I-WBS. We found increased Tg and negative (131)I-WBS in 2 of the 101 patients at the 24th months examination the so called Tg elevated negative (131)I-WBS (TENIS syndrome). The possible explanation of this syndrome is discussed. In conclusion, our study in DTC operated patients does not support the use of repeated diagnostic (131)I-WBS after an undetectable Tg because we found no Tg rebound in patients with negative (131)I-WBS, after 24 months of follow-up with serial measurements of Tg on and of suppression with L thyroxine.
Assuntos
Radioisótopos do Iodo/sangue , Radioisótopos do Iodo/uso terapêutico , Tireoglobulina/sangue , Neoplasias da Glândula Tireoide/radioterapia , Neoplasias da Glândula Tireoide/cirurgia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Cintilografia , Dosagem Radioterapêutica , Radioterapia Adjuvante , Estudos Retrospectivos , Neoplasias da Glândula Tireoide/sangue , Neoplasias da Glândula Tireoide/diagnóstico por imagem , Imagem Corporal Total , Adulto JovemRESUMO
Thyroid status was assessed in adult female rhesus monkey breeders at the California National Primate Research Center at the beginning of the breeding season. The 95% confidence intervals for thyrotropin (TSH), thyroxine (T(4)) and triiodothyronine (T(3)) (n = 66-80) were similar to those previously reported in smaller samples of macaque monkeys. Based on human criteria, 10 of 80 monkeys (12%) were hypothyroid (TSH > 2.0 µIU/mL). Because hypothyroxinaemia can be a risk factor in pregnancy, T(4) status was compared with past breeding history, breeding outcome for that season and general health records in a subset of 42 breeders. Age, weight and parity did not differ between monkeys in the lowest T(4) quartile as compared with those in the upper three quartiles. However, T(4) concentrations were significantly associated with the number of missed menstrual cycles during the previous breeding season. In additional work, three healthy lactating rhesus monkeys were given three different doses of environmental contaminant and thyroid iodine uptake inhibitor, ammonium perchlorate (0.006, 0.34, 12.8 mg/kg/day, respectively) in food for two weeks. Thyroid status variables (TSH, T(4), T(3), thyroid radioactive iodine uptake) were then measured. In the monkey receiving the highest perchlorate dose, iodine uptake was suppressed relative to baseline. The study shows the availability of tools to study thyroid status in rhesus monkeys, the variability of thyroid status in the breeder colony and the potential ability of environmental factors to influence thyroid status.
Assuntos
Disruptores Endócrinos/toxicidade , Macaca mulatta/fisiologia , Percloratos/toxicidade , Compostos de Amônio Quaternário/toxicidade , Glândula Tireoide/efeitos dos fármacos , Hormônios Tireóideos/sangue , Animais , Disruptores Endócrinos/administração & dosagem , Disruptores Endócrinos/análise , Disruptores Endócrinos/farmacocinética , Feminino , Radioisótopos do Iodo/administração & dosagem , Radioisótopos do Iodo/sangue , Radioisótopos do Iodo/farmacocinética , Macaca mulatta/sangue , Percloratos/administração & dosagem , Percloratos/análise , Percloratos/farmacocinética , Compostos de Amônio Quaternário/administração & dosagem , Compostos de Amônio Quaternário/análise , Compostos de Amônio Quaternário/farmacocinética , Reprodução , Glândula Tireoide/fisiologia , Tireotropina/sangue , Tiroxina/sangue , Tri-Iodotironina/sangueRESUMO
The standard treatment for the ablation of thyroid remnant tissue following surgery as well as for the treatment of iodine avid metastases in patients suffering from differentiated thyroid cancer (DTC) is therapy with radioactive iodine. Mostly fixed standard activities are used with the inherent risk of under- or overdosing the patient. Therefore, the rationale for using a dosimetry-based approach is to replace the conventional fixed activity regimen by a patient-tailored approach which allows the administered therapeutic activity to be increased while avoiding unwanted side effects. The purpose of this review was to describe the presently used dosimetric concepts: 1) the blood dosimetry approach (optimizing the "safety" aspect of the treatment); and 2) lesion-based dosimetry (optimizing the "efficacy" of the treatment) and their respective clinical findings. In addition, a simplified method for performing blood dosimetry and its application towards further enhancement of radioiodine therapies are introduced. Finally, a new concept for potentially determining patient-specific radiation sensitivity using blood dosimetry is introduced.
Assuntos
Planejamento da Radioterapia Assistida por Computador/métodos , Neoplasias da Glândula Tireoide/radioterapia , Diferenciação Celular , Humanos , Radioisótopos do Iodo/administração & dosagem , Radioisótopos do Iodo/sangue , Radioisótopos do Iodo/uso terapêutico , Medicina de Precisão/métodos , Dosagem Radioterapêutica , Planejamento da Radioterapia Assistida por Computador/tendências , Neoplasias da Glândula Tireoide/patologia , Neoplasias da Glândula Tireoide/cirurgiaRESUMO
PURPOSE: The residence time of (131)I in the blood is likely to be a measure of the amount of (131)I that is available for uptake by thyroid remnant tissue and thus the radiation absorbed dose to the target tissue in (131)I ablation of patients with differentiated thyroid cancer (DTC). This hypothesis was tested in an investigation on the dependence of the success rate of radioiodine remnant ablation on the radiation absorbed dose to the blood (BD) as a surrogate for the amount of (131)I available for iodine-avid tissue uptake. METHODS: This retrospective study included 449 DTC patients who received post-operative (131)I ablation in our centre in the period from 1993 to 2007 and who returned to us for diagnostic whole-body scintigraphy. The BD was calculated based on external dose rate measurements using gamma probes positioned in the ceiling. Success of ablation was defined as a negative diagnostic (131)I whole-body scan and undetectable thyroglobulin levels at 6 months follow-up. RESULTS: Ablation was successful in 56.6% of the patients. The rate of successful ablation correlated significantly with BD but not with the administered activity. Patients with blood doses exceeding 350 mGy (n = 144) had a significantly higher probability for successful ablation (63.9%) than the others (n = 305, ablation rate 53.1%, p = 0.03). In contrast, no significant dependence of the ablation rate on the administered activity was observed. CONCLUSION: The BD is a more powerful predictor of ablation success than the administered activity.